REG - Trellus Health PLC - Directorate Changes

Trellus HealthAnnouncement

19/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220719:nRSS8916Sa&default-theme=true

RNS Number : 8916S  Trellus Health PLC  19 July 2022

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Directorate Changes

 

LONDON, U.K. AND NEW YORK, U.S. (19 July 2022). Trellus Health plc (AIM:
TRLS), which is commercializing a scientifically validated, resilience-based,
connected health solution for chronic condition management, announces the
following Board and senior management changes:

 

·    Dr. Marla Dubinsky, Co-Founder, who has served the Company and its
shareholders as a Non-executive Director since July 2020, will assume the role
of CEO with immediate effect. To accommodate this new role, Dr. Dubinsky is
reducing other commitments during her tenure as Trellus Health's CEO.

 

·    Aled Stevenson, currently US Executive VP of Sales and Development,
will become Chief Operating Officer (a non-board position) with immediate
effect.

 

·    Monique Fayad is standing down as CEO and from the Board of Trellus
Health with immediate effect, and will continue to offer consultancy services
to the Company for a six-month handover period.

 

·    Richard Evans, who has served as interim CFO since January 2022, has
completed his contract and his duties have transitioned back to Salim Hamir,
Company Secretary and formerly CFO, who is supported by the Company's
financial controller. The Board is reviewing the needs of the business in
terms of the finance function and expects to make a further appointment in due
course.

 

Julian Baines, Non-executive Chairman of Trellus Health, said: "We are very
grateful to Monique for her stewardship of Trellus Health through our
Admission to AIM and the recent delivery of key milestones during very
challenging market conditions and the evolution of our strategy. We wish her
the best in her next venture.  We also thank Richard for his support in
reviewing key aspects of the delivery model and our Direct-to-Consumer (DTC)
capability, and wish him well as he resumes his retirement.

 

"It remains our strategy to focus on both a DTC model as well as a
Business-to-Business model to expand our customer base, and to add further
regional and national multi-year contracts with payers from 2023 onwards, as
well as accelerating our expansion into other chronic conditions such as IBS.
Marla's unrivalled expertise and reputation in this market means she is very
well-placed to lead Trellus Health as we execute our commercialisation
strategy."

 

About Dr. Marla Dubinsky

 

Marla Dubinsky, MD, is a Professor of Pediatrics and Medicine at the Icahn
School of Medicine at Mount Sinai, New York, NY. Dr. Dubinsky received her
medical degree from Queen's University, Canada. She completed her pediatric
residency at Alberta Children's Hospital, Calgary, Canada, and her clinical
fellowship in gastroenterology and nutrition at Sainte-Justine Hospital at the
University of Montreal, Canada. She completed her research fellowship in IBD
at Cedars-Sinai Medical Center in Los Angeles, CA, where she served as the
Director of the Pediatric IBD Center before going to Mount Sinai as the Chief
of Pediatric Gastroenterology and Nutrition at the Mount Sinai Kravis
Children's Hospital and Co-Director of the Susan and Leonard Feinstein IBD
Clinical Center.  Dr. Dubinsky is also the Co-Director of the IBD
Preconception and Pregnancy Planning Clinic at Mount Sinai. She is the
Co-Founder of Mi-Test Health, and Cornerstones Health which is a non-profit
organization dedicated to enhancing and transforming communication between
health care providers, patients, and industry partners through creative,
comprehensive, and expert-based educational program.

 

Dr. Dubinsky has been engaged in inflammatory bowel disease (IBD) clinical and
translational research for over two decades. Dr. Dubinsky's primary research
focuses on developing predictive models and web-based decision support tools
that integrate clinical and biomarkers to predict the natural history of IBD
and response to therapy. She has a keen interest in personalized medicine in
IBD and her research uncovers predictors of rapid disease progression with the
goal of preventing complications by altering treatment plans. Dr. Dubinsky is
the principal investigator of multiple large longitudinal cohorts including
the Road to Prevention Multiplex Family Program at Mount Sinai with over 700
enrolled participants with a goal of using multi-omic data to predict the
development of IBD in unaffected family members and co-investigator of the
Risk Stratification and Identification of Immunogenetic and Microbial Markers
of Rapid Disease Progression in Children with Crohn's Disease (RISK) study and
senior author on the manuscript presenting a model to predict the natural
history of pediatric Crohn's disease. Dr. Dubinsky is very committed to
women's reproductive health in IBD and in addition to her research in this
field she is the Co-founder of WECARE in IBD, an organization dedicated to the
health of women with IBD. She has lectured widely, both nationally and
internationally, and has published in more than 260 peer-reviewed journals,
including Gastroenterology, Lancet, JAMA, The Journal of Pediatric
Gastroenterology and Nutrition, The journal of Crohn's and Colitis,
Inflammatory Bowel Diseases, and the American Journal of Gastroenterology.

 

About Aled Stevenson, Chief Operating Officer

Aled Stevenson, formerly US Executive VP of Sales and Development at Trellus
Health, joined Trellus Health a year ago after a successful 19-year career as
a Regional Business Manager for AstraZeneca, serving initially as Managing
Director, UK, before focusing on commercial activities in his sales and
development role for the US market.

 

The resilience-based, connected health solution for chronic condition
management is based on technology developed by Drs. Dubinsky and Keefer at
Mount Sinai and licensed by Mount Sinai to Trellus Health. Mount Sinai and
Mount Sinai faculty, including Dr. Dubinsky, have a financial interest in
Trellus Health. Mount Sinai also has representation on the Trellus Health
Board of Directors, which includes Dr. Dubinsky.

 

For further information please contact:

 

 Trellus Health plc                                       www.trellushealth.com (http://www.trellushealth.com)
 Julian Baines, Chairman                                  Via Walbrook PR

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR Limited                                      Tel: 020 7933 8780 or trellus@walbrookpr.com (mailto:trellus@walbrookpr.com)
 Paul McManus / Louis Ashe-Jepson                         Mob: 07980 541 893 / 07747 515 393

 

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is the first digital health company focused on the
intersection of chronic physical conditions and mental health. Trellus
Health integrates its proprietary resilience-based methodology with the
technology, tools and team to deliver a whole-person technology-enhanced
experience that results in relieving disease burden and promoting individual
health behaviors that enable thriving in the face of a chronic condition.
Through its TrellusElevate™ connected care platform and companion App, the
company addresses both clinical and behavioral health together, in context, to
improve outcomes and reduce healthcare costs for patients, employers, and the
healthcare system.

 

The Company is initially focused on Inflammatory bowel disease ("IBD"), which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis, but considers its approach to have potential utility and demand
across many chronic conditions, including Irritable Bowel Syndrome ("IBS").

 

The TrellusElevate™ platform is the Company's proprietary connected health
platform that incorporates the GRITT™ methodology and learnings on
resilience from clinical research and practice conducted at the Mount Sinai
IBD Center for more than five years. This proprietary, resilience-driven
methodology has been scientifically validated to demonstrate meaningful
improvements in patient outcomes, 71% reduction in Emergency Department
(A&E) visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for significant cost
savings for healthcare payers. IBD patients treated using the methodology also
experienced a 49% reduction in required opioid use and a 73% reduction in
corticosteroid use 12 months following program completion (source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258) ).

 

The Company was founded by Mount Sinai faculty members Dr. Marla C. Dubinsky,
MD and Dr. Laurie Keefer, PhD, both with decades of combined experience in IBD
and psychogastroenterology, respectively. Trellus Health's patent-pending
GRITT™ resilience assessment and personalized treatment methodology was
developed and validated at the Mount Sinai Health System to build resilience
and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOADZGMNZRGGZZZ